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Abstract
Background: Over recent years, use of the LigaSure™ vessel sealing device has increased in major
abdominal surgery to include pancreaticoduodenectomy (PD). LigaSure™ use during PD has expanded
to include all steps of the procedure, including the division of the uncinate margin. This introduces the
potential for thermal major vascular injury or margin positivity. The aim of the present study was to
evaluate the safety and efficacy of LigaSure™ usage in PD in comparison to established dissection
techniques.
Methods: One hundred and forty-eight patients who underwent PD from 2007 to 2012 at Robert Wood
Johnson University Hospital were identified from a retrospective database. Two groups were recognized:
those in which the LigaSure™ device was used (N = 114), and in those it was not (N = 34). Peri-operative
outcomes were compared.
Results: Vascular intra-operative complications directly caused by thermal injury from LigaSure™ use
occurred in 1.8% of patients. Overall vascular intra-operative complications, uncinate margin positivity,
blood loss, length of stay, and complication severity were not significantly different between groups. The
mean operative time was 77 min less (P < 0.010) in the LigaSure™ group. Savings per case where the
LigaSure™ was used amounted to $1776.73.
Conclusion: LigaSure™ usage during PD is safe and effective. It is associated with decreased operative
times, which may decrease operative costs in PD.
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Introduction
For decades, pancreaticoduodenectomy (PD), i.e. the Whipple
procedure, and the later-established pylorus-preserving PD have
remained the standard operations for resecting peri-ampullary
tumours, but are also indicated in benign disorders such as
chronic pancreatitis and pancreatic cyst disease.1 The operation is
technically challenging in part as a result of the extensive
dissection necessary for the resection and the location of the
pancreas near major vasculature. There are additional oncological
challenges particularly with obtaining a negative uncinate (or ret-
roperitoneal) margin, as this step requires dissection of the unci-
nate process from the superior mesenteric artery (SMA). There
are various techniques described to perform this step, including
the clamp and cut, endovascular stapler, and ultrasonic dissector.2
While no specific technique has proven superior, the margin posi-
tivity rates remain highly variable, ranging from 16% to 85% in
some studies.2–4
The development of the LigaSure™ (ValleyLab) bipolar device
has provided a different means of achieving haemostasis via
sealing vessels by melting collagen and elastin.5,6 Use of the LigaS-
ure™ device has increased inmajor abdominal surgery over recent
years to include hepatic surgery, where its use has been described
in hepatic parenchymal transection.7 Prior to 2011, one case
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report examined its use as the primary means for haemostasis in
PD,8 and another study described its safety in isolated use during
jejunal resection in PD.9 Recently, LigaSure™ usage has been
evaluated in PD in a small-sample pilot study that showed a
decrease in blood loss and operative time in PD when compar-
ing LigaSure™ usage with established dissection techniques.10
However, both the safety of LigaSure™ use pertaining to thermal
major vascular injury and efficacy pertaining to uncinate margin
positivity were not reported. Given the apparent increase in use of
this device in PD, the aim of this study was to evaluate both the
safety and efficacy of LigaSure™ usage in PD in comparison to
established dissection techniques.
Methods
Patient selection and analysis
Analysis was based on data acquired from an institutional review
board-approved database and electronic medical records at
Robert Wood Johnson University Hospital (New Brunswick, NJ,
USA). A total of 148 patients who underwent PD from July 2007
to May 2012 were identified. All of the operations were per-
formed by three surgeons over this time period, composed of
one senior surgeon and two junior faculty members. The LigaS-
ure™ device used in all cases but five was the LigaSure Impact™
hand piece instrument (13.5-mm shaft diameter, jaw angle
curved 14 degrees). In the remaining five cases, the LigaSure
Small Jaw™ was used. Upon review of operative records, patients
were placed into one of two groups: cases in which the LigaS-
ure™ device was primarily used for dissection and haemostasis
(N = 114), and cases in which it was not (N = 34). In six of the
patients in the non-LigaSure™ (NL) group, the LigaSure™
device was minimally used during each operation, either to
mobilize the jejunum or to facilitate entering the lesser sac, and
not as the primary means for dissection and haemostasis. In
none of those cases was the LigaSure™ device used around the
superior mesenteric vein (SMV), SMA, portal vein (PV) or in
uncinate margin transection. Vascular intra-operative complica-
tions were identified from operative reports and discussions with
operating surgeons, as well as any thermal injuries directly as a
result of LigaSure™ usage. We defined a vascular intra-operative
complication as an injury to a major vessel (SMV, SMA and PV)
or direct branch thereof. The uncinate margin positivity rate,
estimated blood loss, operative time, complications and length of
stay were compared between the groups. Statistical analysis
included Student’s t-tests for continuous variables, chi-squared
tests for categorical data, and Wilcoxon–Mann–Whitney rank
sum tests for ordinal variables.
LigaSure™ versus established techniques
PD technique was not standardized among surgeons. Established
techniques for dissection and haemostasis involved clips, ties, scis-
sors, and suture ligatures. In cases where the LigaSure™ was used,
the instrument was utilized in various aspects of the operation but
most crucially the dissection around the PV, SMV and SMA.
The second most common step in the operation in which the
LigaSure™ was used was during the division of the mesenteric
vessels of the proximal jejunum and third/fourth portion of the
duodenum. In this study, particular attention was given to the step
in the operation during dissection of the uncinate from the SMA,
as the use of the device in this step has the potential for thermal
injury to the adjacent major vasculature (PV/SMV), and this is the
crucial step that can potentially influence the margin, particularly
in cases of pancreatic adenocarcinoma.
Results
The pattern of LigaSure™ use (Fig. 1) indicates that by 2010, the
LigaSure™ was being used routinely for all aspects of the dissec-
tion, including the uncinate margin, by all three surgeons. From
2007 to 2009, LigaSure™ usage has steadily increased, reflecting a
gradual shift in preference for use of the device. During this earlier
period, the selection of LigaSure™ was not influenced by any
particular factor, including histology, patient factors, or level of
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Figure 1 Evolution of LigaSure™ usage in pancreaticoduodenectomy (PD)
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Table 1 shows demographics and diagnoses of patients in each
group. There were no significant differences in the comorbidities
and pre-operative albumin between the two groups. Likewise, the
proportion of patients with a diagnosis of pancreatic adenocarci-
noma between the two groups was similar (P = 0.631). Of patients
diagnosed with pancreatic adenocarcinoma, the percentage of
patients who underwent neoadjuvant therapy was similar between
the groups (P = 0.945).
Table 2 compares the peri-operative outcomes between the two
groups. Vascular intra-operative complications directly as a result
of thermal injury from LigaSure™ use occurred in 2/114 patients
(1.8%). The first case occurred in a patient with pancreatic adeno-
carcinoma previously explored for resection, but was aborted due
to SMV/PV involvement with a Roux-en-Y hepaticojejunostomy
and gastrojejunostomy created. That patient then underwent
chemotherapy and radiation. Repeat imaging indicated resectabil-
ity, and the patient was brought to the operating room for a
second attempt at resection. It was during this operation that a
thermal injury to the PV occurred during the dissection of the
uncinate margin. This injury was created using the LigaSure™ on
the uncinate margin tissue parallel to the PV, without retraction of
the PV. Vascular control was obtained with suture ligatures, but
Table 1 Patient group demographics
LigaSure™ Non-LigaSure™ P-value
Number of patients 114 34
Mean age (range) 64.4 (38–88) 61 (13–83) 0.287
Number of females (%) 62 (54.4) 15 (44.1) 0.293
Past medical history, n (%)
Coronary artery disease 14 (12.3) 6 (17.6) 0.422
Chronic obstructive pulmonary disease, asthma, and/or obstructive sleep apnoea 18 (15.8) 6 (17.6) 0.797
Diabetes mellitus 39 (34.2) 11 (32.4) 0.841
Smoking 31 (27.2) 5 (14.7) 0.136
Mean pre-operative serum albumin level, g/dl (range) 3.5 (1.8–4.5) 3.4 (0.6–4.5) 0.328
Neoadjuvant therapy (pancreatic adenocarcinoma), n (%) 7 (6.1) 2 (5.9) 0.945
Diagnosis, n (%)
Adenocarcinoma 73 (64.0) 21 (61.8)
Pancreatic 59 (51.8) 16 (47.1) 0.631
Duodenal 12 (10.5) 4 (11.8)
Common bile duct 2 (1.8) 1 (2.9)
Intraductal papillary mucinous neoplasm 12 (10.5) 4 (11.8)
Endocrine neoplasm 8 (7.0) 2 (5.9)
Other tumours 8 (7.0) 6 (17.6)
Table 2 Peri-operative outcomes
LigaSure™ Non-LigaSure™ P-value
Number of patients 114 34
Vascular intra-operative complications, n (%) 6 (5.3) 5 (14.7) 0.065
Thermal injury caused by LigaSure™, n (%) 2 (1.8) –
Uncinate margin positivity for pancreatic adenocarcinoma, n (%) 12 (20.3) 4 (25.0) 0.687
Venous resection, n (%) 10 (8.8) 2 (5.9) 0.588
Mean estimated blood loss, ml (range) 926 (100–15000) 1163 (150–4000) 0.279
Mean operative time, min (range) 416 (232–779) 493 (313–767) <0.010
Median length of stay, days (range) 8 (4–68) 11.5 (5–66) 0.186
Clavien–Dindo classification at 90 days, n (%)
Clavien 0 35 (30.7) 11 (32.4) 0.855
Clavien 1–2 42 (36.8) 13 (38.2) 0.883
Clavien 3–5 37 (32.5) 10 (29.4) 0.738
Mean Clavien classification at 90 days (range) 1.9 (1–5) 1.8 (1–5) 0.717
HPB 749
HPB 2013, 15, 747–752 © 2013 International Hepato-Pancreato-Biliary Association
the patient became haemodynamically unstable, and the case was
aborted. This patient subsequently died of multisystem organ
failure. In the second case, the LigaSure™ was used for dissection
around the uncinate process and created a thermal injury on the
main jejunal tributary to the superior mesenteric vein. After a
significant haemorrhage, control was obtained with suture liga-
tures. The patient remained haemodynamically stable during the
event and for the entirety of the case.
Overall, vascular intra-operative complications occurred in 6
LigaSure™ patients and 5 NL patients (P = 0.065). Venous resec-
tion was performed in 10 LigaSure™ patients and 2 NL patients
(P = 0.588). Uncinate margin positivity for pancreatic adenocar-
cinoma was not significantly different between the groups (P =
0.687). Mean estimated blood losses were 926 and 1163 ml
(P = 0.279), and mean operative times were 416 and 493 min,
(P < 0.010) in LigaSure™ and NL patients, respectively. Median
lengths of stay in days were 8 for LigaSure™ patients and 11.5
for NL patients (P = 0.186). The mean post-operative Clavien–
Dindo complication severity grades at 90 days were 1.9 and 1.8
in LigaSure™ patients and NL patients, respectively (P = 0.717).
Detailed post-operative complications are shown in Table 3.
The pancreatic anastomotic leak/abscess/fistula rate was not
significantly different between the groups (P = 0.936). Thirty-
day mortality was not significantly different between the groups
(P = 0.446).
Discussion
The current literature examining LigaSure™ usage in PDs is
sparse.8,9 A recent pilot case–control study10 examined the safety of
LigaSure™ usage in seven patients undergoing PD compared with
seven via conventional techniques. Significant decreases in opera-
tive time, blood loss and costs were found when the LigaSure™
device was used. Given the small size of this study, it is difficult to
make a reliable assessment of the safety and efficacy of the instru-
ment in PD. These same authors have initiated a larger prospective
randomized study to more rigorously evaluate the device;11
however at this time, there are no other studies that have exam-
ined both the safety and efficacy of this device specifically in PD.
LigaSure™ usage has been increasing in major abdominal
surgery, with various studies reporting on its safety.6,7,12,13 In one
study examining the safety of LigaSure™ dissection in Ivor-
Lewis esophagectomies compared with established techniques,
LigaSure™ usage was associated with a significant decrease in
operative time and blood loss.12 Such results have been reported in
gastric and colorectal cancer operations with extended lymph
node dissections as well.13 LigaSure™ usage is also safe during
hepatic parenchyma dissection.7 The LigaSure™ device has even
been shown to produce decreased lateral thermal damage on the
human peritoneum compared with monopolar diathermy.14
Use of the LigaSure™ device is a safe and effective alternative to
established dissection techniques in PD. It is associated with
decreased operative times and a similar uncinate margin positivity
rate. While not significantly different, we did find that LigaSure™
usage was associated with over 200 ml less blood loss intra-
operatively, a decreased intra-operative vascular injury rate, and a
3.5-day shorter length of hospital stay. These measured variables
for both the LigaSure™ and non-LigaSure™ groups were similar
to established norms for peri-operative complications and length
of stay.15–17
The decision to evaluate the LigaSure™ in PD is based upon the
increased use of the device during the surgery over time as shown
in Fig. 1.As experience with it has grown, so too has its application
to virtually all steps in the dissection, including the uncinate
margin. This is a crucial step in the operation where there is
potential for thermal injury to the PV/SMV. These data would
indicate that major vascular injury, particularly PV/SMV injury,
was not statistically significantly different when using the LigaS-
ure™ compared with NL techniques. Two vascular injuries
occurred directly from thermal injury with the use of the device,
and we feel this is important to report. As experience using the
LigaSure™ has grown, techniques have been developed to help
avoid such types of injury, and these have been illustrated in
Figs 2–4. Nonetheless, one of these complications was a death that
occurred in the setting of a re-exploration after radiation. Thus,
for the surgeon just starting to incorporate the LigaSure™ in
the uncinate dissection, we would discourage the use of the
LigaSure™ in this portion of the operation for complex cases
such as this.
Figure 2 demonstrates the proper technique to apply when
using the LigaSure™ in the uncinate margin dissection. The
SMV/PV is dissected from the pancreas, and the vein is retracted
with either a vessel loop or vein retractor. The LigaSure™ can be
used either perpendicular to the tissue along the SMA or parallel
to it. This provides the optimal method of maintaining haemos-
tasis and minimizing thermal injury. The improper technique is
shown in Fig. 3, in which the LigaSure™ is used without retraction
Table 3 Post-operative complications, n (%)
LigaSure™ Non-LigaSure™
Number of patients 114 34
Cardiovascular 19 (16.7) 7 (20.6)
Pulmonary 16 (14.0) 9 (26.5)
Gastrointestinal 42 (36.8) 17 (50.0)
Liver 7 (6.1) 2 (5.9)
Pancreas 20 (17.5) 4 (11.8)
Anastomotic leak/abscess/fistula,
P = 0.936
14 (12.3) 4 (11.8)
Other infections 34 (29.8) 9 (26.5)
Miscellaneous 8 (7.0) 1 (2.9)
30-day mortality, P = 0.446 6 (5.3) 3 (8.8)
90-day mortality 5 (4.4) –
Total 157 52
Complications per patient 1.4 1.5
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of the SMV/PV. Figure 4 illustrates the use of the LigaSure™
device in dividing mesenteric vessels after division of the jejunum.
The other reason to investigate the device at this step of the
operation is because of its potential impact on the uncinate
margin positivity rate. The uncinate margin positivity rate in dif-
ferent series of PD has varied significantly.2–4 There are likely
several reasons for this, such as the inclusion of patients with all
types of peri-ampullary tumours, patients having undergone neo-
adjuvant therapy, and a lack of standard dissection techniques.
Given these factors, we chose to limit our analysis of the uncinate
margin positivity rate to only those patients undergoing the
operation for pancreatic adenocarcinoma. There was no differ-
ence between the two groups in the percentage of patients with a
diagnosis of pancreatic adenocarcinoma, and no difference in the
uncinate margin positivity rate between the LigaSure™ and NL
groups, both of which fell within reported rates in the literature.2–4
It is our practice to use neoadjuvant therapy in patients with
borderline or locally advanced tumours; the majority of our
patients (88%) with pancreatic adenocarcinoma did not receive
pre-operative therapy. With respect to the different techniques to
transect the uncinate margin, our group of non-LigaSure™ tech-
niques was fairly uniform with the majority using clamps and ties
and only one case where the vascular stapler was used.
It was found that the use of the LigaSure™ in PD is associated
with a significant decrease in operative time when compared with
the NL group. The mean operative time was 77 min shorter in the
LigaSure™ versus NL group. Our findings are consistent not only
with reports of the device in PDs but in other major abdominal
surgery.6,7,13 At our institution, as demonstrated in Table 4, this
would save $2246.09 per case and more than offset the cost of the
device ($472.42), with mean overall savings per case of $1773.67.
Gehrig et al. also found that the use of the device resulted in
reduced blood loss.10 These data indicated a trend towards this
finding but was not statistically significant.
We acknowledge several weaknesses of this study, the first being
its retrospective design. Given the rapid adoption of this tech-
nique at this institution, we had a relatively small group of NL
Figure 2 Proper technique: during uncinate margin dissection, a
thermal injury can occur as the LigaSure™ comes in close contact
with the portal and superior mesenteric vein (SMV) confluence. It is
essential to retract the vein as depicted here. Division of the uncinate
margin can be done taking perpendicular bites as indicated here, or
by placing the device parallel to the superior mesenteric artery
(SMA)
Figure 3 Improper technique: parallel positioning of the LigaSure™
without retracting the vein while dividing tissue at the uncinate
margin. SMV, superior mesenteric vein; SMA, superior mesenteric
artery
Figure 4 Use of the LigaSure™ to seal vessels of the proximal
jejunum and duodenum after division of the jejunum. These vessels
are small and numerous, with ligation and division by conventional
ties tedious. Use of the LigaSure™ greatly speeds up this step of the
operation
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patients to compare. We could have gone back further in time to
collect data on more patients in whom the device was not used,
however, those cases were done by a different group of surgeons,
and this would have introduced another element of bias. Due to
increasing LigaSure™ usage at this institution over time, experi-
ence may have contributed to the decreased operative times. Two
of the three surgeons were junior faculty members and in the early
years of practice.We acknowledge that the learning curve of these
surgeons in performing a PD is a complicating factor, and
improvement in operative times could very well have been influ-
enced by this learning curve. Of note, however, the senior surgeon
in this group has over two decades of experience performing PD,
and he performed the majority of cases in this dataset, both
overall (54.4%) and in the NL group (73.5%). Thus, the longer
operative times observed in the NL group were less likely influ-
enced by the factor of surgeon experience.
While our pancreatic anastomotic leak rates were not signifi-
cantly different between the two groups, data regarding risk strati-
fication of anastomotic leaks, including gland texture and duct
size, were not routinely mentioned in operative reports. However,
blood loss and histology are two factors that have been identified
as independent predictors of a pancreatic anastomotic leak,18 and
our data demonstrates no significant difference between the two
groups. Nonetheless, a prospective randomized trial is underway
in Europe to evaluate the use of the LigaSure™ in PD, and we look
forward to this report.11
LigaSure™ usage in PD is safe, effective, and is associated with
decreased operative time. The present study incorporates the
largest population of PD patients to date in examining the
safety of LigaSure™ usage, and is the first to report on its efficacy
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